For the year ending 2025-12-31, AMRX had $194,519K increase in cash & cash equivalents over the period. $269,929K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net income (loss) | 127,933 |
| Depreciation and amortization | 223,572 |
| Unrealized foreign currency (gain) loss | 7,453 |
| Amortization of debt issuance costs and discount | 22,431 |
| Reclassification of cash flow hedge | -1,229 |
| Loss on refinancing | -31,365 |
| Intangible asset impairment charges | 22,784 |
| Change in fair value of contingent consideration | 0 |
| Stock-based compensation | 31,953 |
| Inventory provision | 85,962 |
| Other operating charges and credits, net | -4,732 |
| Trade accounts receivable, net | 120,566 |
| Inventories | 87,026 |
| Prepaid expenses, other current assets and other assets | 19,163 |
| Related party receivables | 13 |
| Accounts payable, accrued expenses and other liabilities | 21,321 |
| Related party payables | 931 |
| Net cash provided by operating activities | 339,992 |
| Purchases of property, plant and equipment | 70,063 |
| Acquisition of intangible assets | 15,514 |
| Deposits for future acquisition of property, plant, and equipment | 28,780 |
| Proceeds from sale of property, plant, equipment and other | 2,094 |
| Proceeds from sale of subsidiary | 0 |
| Net cash used in investing activities | -112,263 |
| Proceeds from issuance of debt | 2,694,750 |
| Payments of principal on debt, revolving credit facility, financing leases and other | -2,811,508 |
| Payments of deferred financing, refinancing costs and debt extinguishment costs | 74,973 |
| Borrowings on revolving credit facility | 218,000 |
| Proceeds from exercise of stock options | 1,960 |
| Employee payroll tax withholding on restricted stock unit and performance stock unit vesting | 22,278 |
| Tax and other distributions to non-controlling interests | 43,848 |
| Payment of principal on notes payable - related party | 0 |
| Proceeds from alliance party | 6,367 |
| Net cash used in financing activities | -31,530 |
| Effect of foreign exchange rate on cash | -1,680 |
| Net increase in cash, cash equivalents, and restricted cash | 194,519 |
| Cash, cash equivalents, and restricted cash - beginning of period | 118,420 |
| Cash, cash equivalents, and restricted cash - end of period | 312,939 |
Amneal Pharmaceuticals, Inc. (AMRX)
Amneal Pharmaceuticals, Inc. (AMRX)